ClinicalTrials.gg
TerminatedNCT05486208Updated Oct 13, 2026Results posted

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1 interventional study of LY3844583 and LY3844583 in Healthy and Dermatitis, Atopic, sponsored by Eli Lilly and Company. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Why this study was terminated
Study terminated due to lack of efficacy signal in atopic dermatitis participants.
Updated Oct 13, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Dermatitis, Atopic by Eli Lilly and Company — 1 open to participants now, 2 under way, 2 of them phase 3. Dermatitis, Atopic · Eli Lilly and Company.

Enrollment
26th of 30
86 · median 283
Started
2022
with 2 others
Phase 1
3 of 30
none open now
Registered
23rd of 30
by date

Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 26th largest by enrollment, is one of 3 that started in 2022, is one of 3 in phase 1, and was the 23rd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 30 studies in Dermatitis, Atopic by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dermatitis, Atopic by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis (AtD). The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 85, 113, and 183 days with 10, 18, and 14 visits for each participant in parts A, B, and C, respectively.

03

Conditions studied

  • Healthy
  • Dermatitis, Atopic

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants (Parts A and B):

    • Are male or female not of
    • Inclusion of healthy Japanese participants, the participant must be first-generation Japanese, defined as the participant's biological parents and all of the participant's biological grandparents must be of exclusive Japanese descent, and must have been born in Japan.
    • Inclusion of healthy Chinese participants, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China.
    • Must have a of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive. For healthy Japanese participants, have a body mass index of 18.0 to 28.0 kg/m², inclusive, and a body weight of 50 kg to 85 kg, inclusive.
  • Atopic dermatitis participants (Part C):

    • Must have a body mass index of 18.0 to 45.0 kg/m², inclusive
    • Are male or female participants including those of child bearing potential
    • Must have a diagnosis of AtD for at least 12 months with either poor response to topical treatments or inability to use topical treatments
    • Must agree to use moisturizer daily throughout the treatment period

Exclusion criteria

Exclusion Criteria:

  • All participants:

    • Have or used to have health problems or laboratory test results or (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
    • Have active or latent tuberculosis
    • Have had any cancer within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrence or disease within the 3 years prior to baseline
    • Have one of the following viral infections: virus, virus or .
    • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 30 days or 5 half-lives (whichever is longer) prior to dosing
    • Must not have previously completed a clinical trial with a molecule targeting interleukin-33 and/or the interleukin-33 receptor (ST2)
    • Are currently participating in or completed a clinical trial within the last 30 days
    • Have received a vaccine containing a live (attenuated) virus within 28 days of screening or intend to receive during the course of the study
  • Atopic dermatitis participants:

    • Must not have received certain topical medications for AtD within 2 weeks prior to randomization
    • Must not have received certain oral medications for AtD or received phototherapy within 4 weeks prior to randomization
    • Must not have received any antibody-based biologic agents (marketed or ) within 5 half lives (t1/2) of the drug prior to randomization
    • Must not have received intravenous, intramuscular, or intra-articular in the past 6 weeks prior to randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3)

    Healthy participants received a single matching dose of Placebo via subcutaneous (SC) injection on Day 1.

    Drug: Placebo

  • Placebo comparator
    Part A: Placebo IV (SAD - Cohort 4-5)

    Healthy participants received a single matching dose of Placebo via intravenous (IV) infusion on Day 1.

    Drug: Placebo

  • Experimental
    Part A: 30 mg LY3844583 SC (SAD - Cohort 1)

    Healthy participants received a single dose of 30 milligrams (mg) LY3844583 via SC injection on Day 1.

    Drug: LY3844583

  • Experimental
    Part A: 100 mg LY3844583 SC (SAD - Cohort 2)

    Healthy participants received a single dose of 100 mg LY3844583 via SC injection on Day 1.

    Drug: LY3844583

  • Experimental
    Part A: 300 mg LY3844583 SC (SAD - Cohort 3)

    Healthy participants received a single dose of 300 mg LY3844583 via SC injection on Day 1.

    Drug: LY3844583

  • Experimental
    Part A: 300 mg LY3844583 IV (SAD - Cohort 4)

    Healthy participants received a single dose of 300 mg LY3844583 via IV infusion on Day 1.

    Drug: LY3844583

  • Experimental
    Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)

    Healthy participants received a single dose of 1000 mg LY3844583 via IV infusion on Day 1.

    Drug: LY3844583

  • Experimental
    Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2)

    Healthy participants received a matching dose of Placebo via IV infusion once every 2 weeks (Q2W) on Days 1, 15, and 29 in Cohort 1, or once every week (QW) on Days 1, 8, 15, 22, and 29 in Cohort 2.

    Drug: Placebo

  • Experimental
    Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)

    Healthy participants received 300 mg LY3844583 via IV infusion Q2W on Days 1, 15, and 29.

    Drug: LY3844583

  • Experimental
    Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)

    Healthy participants received 1000 mg LY3844583 via IV infusion QW on Days 1, 8, 15, 22, and 29.

    Drug: LY3844583

  • Experimental
    Part C: Placebo IV Q2W

    Participants with Atopic Dermatitis (AtD) received a matching dose of Placebo via IV infusion Q2W for 12 weeks.

    Drug: Placebo

  • Experimental
    Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

    Participants with AtD received 1000 mg LY3844583 via IV infusion Q2W for 12 weeks.

    Drug: LY3844583

Interventions

  • DrugLY3844583

    Administered SC

  • DrugLY3844583

    Administered IV

  • DrugPlacebo

    Administered SC

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    * An AE was any untoward medical occurrence in a participant who was administered an investigational product that did not necessarily have a causal relationship with the treatment. A TEAE was defined as an AE that occurred post-dose or was present prior to dosing and became more severe post-dose. * An SAE was any AE from the study that resulted in one of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (i.e., immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that might not have been immediately life-threatening or resulted in death or hospitalization but might have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above. * A summary of SAEs and other non-serious AEs, regardless of causality, is located in the reported Adverse Events section of this record.

    Time frame: Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)

    PK: Cmax of LY3844583 in Part A (SAD)

    Time frame: Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)

    PK: AUC(0-inf) of LY3844583 in Part A (SAD)

    Time frame: Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)

  3. PK: Cmax of LY3844583 - Part B (MAD - Cohort 1)

    PK: Cmax of LY3844583 in Part B (MAD - Cohort 1)

    Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)

  4. PK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)

    PK: AUCτ of LY3844583 (τ = 336 hrs) in Part B (MAD - Cohort 1)

    Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose)

  5. PK: Cmax of LY3844583 - Part B (MAD - Cohort 2)

    PK: Cmax of LY3844583 in Part B (MAD - Cohort 2)

    Time frame: Part B (MAD - Cohort 2): Day 1 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)

  6. PK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)

    PK: AUCτ of LY3844583 (τ = 168 hrs) in Part B (MAD - Cohort 2). For Day 29, no PK samples were collected at 168 hours post dose, so data up to 144 hours post-dose were reported and used for AUC 0-τ parameter assessments.

    Time frame: Part B (MAD - Cohort 2): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144 hours postdose)

  7. PK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

    PK: Cmax of LY3844583 in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

    Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)

  8. PK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

    PK: AUCτ of LY3844583 (τ = 336 hours) in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1).For Day 85: No PK samples were collected beyond 72 hours post-dose, so data up to 72 hours post-dose were reported and used for AUC 0-τ parameter assessments.

    Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)

07

Results

Posted Oct 13, 2026
Limitations and caveats
Based on an analysis of the observed efficacy data from previous cohorts, the sponsor had determined that the results did not support continuing the trial, which led to the premature termination and incomplete execution of Part C.

Participant flow

Part C of the trial had been terminated early as, based on an analysis of the observed efficacy data from previous cohorts, the sponsor had determined that the results did not support continuing the trial.

Participant flow — Overall Study
MilestonePart A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)
Started65666611466618
Received at least one dose of study drug65666611466618
Completed6566661146626
Not completed0000000000412
Withdrew: Adverse event000000000001
Withdrew: Withdrawal by subject000000000002
Withdrew: Study terminated by sponsor000000000049

Outcome measures

PrimaryNumber of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

* An AE was any untoward medical occurrence in a participant who was administered an investigational product that did not necessarily have a causal relationship with the treatment. A TEAE was defined as an AE that occurred post-dose or was present prior to dosing and became more severe post-dose. * An SAE was any AE from the study that resulted in one of the following: death, initial or prolonged inpatient hospitalization, a life-threatening experience (i.e., immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that might not have been immediately life-threatening or resulted in death or hospitalization but might have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above. * A summary of SAEs and other non-serious AEs, regardless of causality, is located in the reported Adverse Events section of this record.

Time frame:
Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days)
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)
TEAEs0010036012410
SAEs000000000000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)

PK: Cmax of LY3844583 in Part A (SAD)

Time frame:
Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)
nanograms per milliliter (ng/mL)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)3190 ± 2910800 ± 3451400 ± 27118000 ± 26410000 ± 17
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)

PK: AUC(0-inf) of LY3844583 in Part A (SAD)

Time frame:
Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)
hours*nanograms per milliliter (h*ng/mL)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)984000 ± 274330000 ± 3719700000 ± 2624100000 ± 1996700000 ± 23
SecondaryPK: Cmax of LY3844583 - Part B (MAD - Cohort 1)

PK: Cmax of LY3844583 in Part B (MAD - Cohort 1)

Time frame:
Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Cmax of LY3844583 - Part B (MAD - Cohort 1)
nanograms per milliliter (ng/mL)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)
Day 1129000 ± 15
Day 29156000 ± 25
SecondaryPK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)

PK: AUCτ of LY3844583 (τ = 336 hrs) in Part B (MAD - Cohort 1)

Time frame:
Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
PK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)
hours*nanograms per milliliter (h*ng/mL)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)
Day 116000000 ± 23
Day 2923900000 ± 30
SecondaryPK: Cmax of LY3844583 - Part B (MAD - Cohort 2)

PK: Cmax of LY3844583 in Part B (MAD - Cohort 2)

Time frame:
Part B (MAD - Cohort 2): Day 1 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Cmax of LY3844583 - Part B (MAD - Cohort 2)
nanograms per milliliter (ng/mL)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)
Day 1509000 ± 19
Day 29888000 ± 9
SecondaryPK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)

PK: AUCτ of LY3844583 (τ = 168 hrs) in Part B (MAD - Cohort 2). For Day 29, no PK samples were collected at 168 hours post dose, so data up to 144 hours post-dose were reported and used for AUC 0-τ parameter assessments.

Time frame:
Part B (MAD - Cohort 2): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144 hours postdose)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
PK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)
hours*nanograms per milliliter (h*ng/mL)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)
Day 142900000 ± 14
Day 2991800000 ± 13
SecondaryPK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

PK: Cmax of LY3844583 in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

Time frame:
Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
nanograms per milliliter (ng/mL)Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
Day 1449000 ± 19
Day 85683000 ± 11
SecondaryPK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

PK: AUCτ of LY3844583 (τ = 336 hours) in Part C: 1000 mg LY3844583 IV Q2W (Cohort 1).For Day 85: No PK samples were collected beyond 72 hours post-dose, so data up to 72 hours post-dose were reported and used for AUC 0-τ parameter assessments.

Time frame:
Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
Reported as:
Geometric mean · hours*nanograms per milliliter (h*ng/mL)
PK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
hours*nanograms per milliliter (h*ng/mL)Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)
Day 157000000 ± 20
Day 85112000000 ± 12

Adverse events

Collected over Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo SC ( SAD -Cohort 1-3)0/6 (0%)0/6 (0%)0/6 (0%)
Part A: Placebo IV (SAD - Cohort 4-5)0/5 (0%)0/5 (0%)0/5 (0%)
Part A: 30 mg LY3844583 SC (SAD - Cohort 1)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: 100 mg LY3844583 SC (SAD - Cohort 2)0/6 (0%)0/6 (0%)0/6 (0%)
Part A: 300 mg LY3844583 SC (SAD - Cohort 3)0/6 (0%)0/6 (0%)0/6 (0%)
Part A: 300 mg LY3844583 IV (SAD - Cohort 4)0/6 (0%)0/6 (0%)3/6 (50%)
Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)0/11 (0%)0/11 (0%)6/11 (54.5%)
Part B: Placebo IV (MAD - Cohort 1-2)0/4 (0%)0/4 (0%)0/4 (0%)
Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part C: Placebo IV Q2W0/6 (0%)0/6 (0%)4/6 (66.7%)
Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)0/18 (0%)0/18 (0%)10/18 (55.6%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPart A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)
EpistaxisRespiratory, thoracic and mediastinal disorders0/60/50/60/60/60/63/110/40/60/60/60/18
Dermatitis atopicSkin and subcutaneous tissue disorders0/60/50/60/60/60/60/110/40/60/61/64/18
Conjunctival haemorrhageEye disorders0/60/50/60/60/60/60/110/40/61/60/61/18
DiarrhoeaGastrointestinal disorders0/60/51/60/60/60/60/110/40/60/60/60/18
Influenza like illnessGeneral disorders0/60/50/60/60/61/60/110/40/60/60/60/18
Vessel puncture site erythemaGeneral disorders0/60/50/60/60/60/60/110/41/60/60/60/18
NasopharyngitisInfections and infestations0/60/50/60/60/60/60/110/40/60/60/63/18
Oral herpesInfections and infestations0/60/50/60/60/60/60/110/40/60/61/60/18
Glucose urine presentInvestigations0/60/50/60/60/60/60/110/40/60/61/60/18
Grip strength decreasedInvestigations0/60/50/60/60/60/60/110/40/60/61/60/18

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Part A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)Total
Mean42.3 ± 13.437.4 ± 18.135.2 ± 11.640.0 ± 15.339.3 ± 5.038.3 ± 15.642.1 ± 15.245.8 ± 15.741.8 ± 9.138.8 ± 13.337.2 ± 10.137.0 ± 9.439.3 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)Total
Female021101410121023
Male63556573654863
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)Total
Hispanic or Latino10312011200011
Not Hispanic or Latino5535461034661875
Unknown or Not Reported0000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)Total
American Indian or Alaska Native0001000000001
Asian230103811561848
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American20122210110012
White22524123400025
More than one race0000000000000
Unknown or Not Reported0000000000000
Region of Enrollment
Region of Enrollment(Participants)Part A: Placebo SC ( SAD -Cohort 1-3)Part A: Placebo IV (SAD - Cohort 4-5)Part A: 30 mg LY3844583 SC (SAD - Cohort 1)Part A: 100 mg LY3844583 SC (SAD - Cohort 2)Part A: 300 mg LY3844583 SC (SAD - Cohort 3)Part A: 300 mg LY3844583 IV (SAD - Cohort 4)Part A: 1000 mg LY3844583 IV (SAD - Cohort 5)Part B: Placebo IV (MAD - Cohort 1-2)Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1)Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2)Part C: Placebo IV Q2WPart C: 1000 mg LY3844583 IV Q2W (Cohort 1)Total
United States656666114660062
Japan000000000061824
08

Study locations

3 sites
  • Parexel Early Phase Unit at Glendale
    Glendale, California 91206-4140, United States
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka, Osaka 532-0003, Japan
  • P-one clinic
    Hachiōji, Tokyo 192-0071, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Jan 2024, 17 months.

Results were first posted in Oct 2026, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 3, 2022
StartActual
Aug 11, 2022
Primary completionActual
Jan 20, 2024
CompletionActual
Jan 20, 2024
Results first posted
Oct 13, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 13, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Japan)
  • Medical Corporation Heishinkai OPHAC Hospital · Osaka, Japan
  • P-one clinic · Hachiōji, Japan
Show 2 removed
  • Medical Corporation Heishinkai OPHAC Hospital · Osaka-shi, Japan
  • P-one clinic · Hachioji, Japan
Oct 13, 2026
Enrollment
102→86
Oct 13, 2026
Eligibility
2 inclusion criteria edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedinclusionInclusion of healthy ChinseChinese participants, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China.
  • EditedMust have a diagnosis of ADAtD for at least 12 months with either poor response to topical treatments or inability to use topical treatments
Exclusion criteria
  • EditedMust not have received certain topical medications for ADAtD within 2 weeks prior to randomization
  • EditedMust not have received certain oral medications for ADAtD or received phototherapy within 4 weeks prior to randomization
Oct 13, 2026
Interventions
Added Drug: LY3844583·Drug: Placebo. Arms added: Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3)·Part A: Placebo IV (SAD - Cohort 4-5)·Part A: 30 mg LY3844583 SC (SAD - Cohort 1)·Part A: 100 mg LY3844583 SC (SAD - Cohort 2)·Part A: 300 mg LY3844583 SC (SAD - Cohort 3)·and 7 more
All 12

Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) · Part A: Placebo IV (SAD - Cohort 4-5) · Part A: 30 mg LY3844583 SC (SAD - Cohort 1) · Part A: 100 mg LY3844583 SC (SAD - Cohort 2) · Part A: 300 mg LY3844583 SC (SAD - Cohort 3) · Part A: 300 mg LY3844583 IV (SAD - Cohort 4) · Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) · Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) · Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) · Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) · Part C: Placebo IV Q2W · Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

; arms removed: LY3844583 (Part A)·LY3844583 (Part B)·LY3844583 (Part C)·Placebo (Part A)·Placebo (Part B)·and 1 more
All 6

LY3844583 (Part A) · LY3844583 (Part B) · LY3844583 (Part C) · Placebo (Part A) · Placebo (Part B) · Placebo (Part C)

Oct 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants withWith One or More Adverse Events (AEs), - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s)Events (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Day 186 → Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days)
Oct 13, 2026
Documents
Secondary outcomes
2 edited, 6 added
What changed in the outcomes
  • EditedPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)Time frame: Pre-dose on Day 1 up to 186 days post-dose → Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
  • EditedPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)Time frame: Pre-dose on Day 1 up to 186 days post-dose → Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
  • AddedPK: Cmax of LY3844583 - Part B (MAD - Cohort 1)Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
  • AddedPK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose)
  • AddedPK: Cmax of LY3844583 - Part B (MAD - Cohort 2)Time frame: Part B (MAD - Cohort 2): Day 1 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
  • AddedPK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)Time frame: Part B (MAD - Cohort 2): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144 hours postdose)
  • AddedPK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
  • AddedPK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Results posted
    2 sites added, 2 sites removed
    Show 2 added (2 Japan)
    • Medical Corporation Heishinkai OPHAC Hospital · Osaka, Japan
    • P-one clinic · Hachiōji, Japan
    Show 2 removed
    • Medical Corporation Heishinkai OPHAC Hospital · Osaka-shi, Japan
    • P-one clinic · Hachioji, Japan
    Enrollment 102→86
    Eligibility 2 inclusion criteria edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedinclusionInclusion of healthy ChinseChinese participants, the participant must be at a minimum, third-generation Chinese, defined as all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China.
    • EditedMust have a diagnosis of ADAtD for at least 12 months with either poor response to topical treatments or inability to use topical treatments
    Exclusion criteria
    • EditedMust not have received certain topical medications for ADAtD within 2 weeks prior to randomization
    • EditedMust not have received certain oral medications for ADAtD or received phototherapy within 4 weeks prior to randomization
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants withWith One or More Adverse Events (AEs), - Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s)Events (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Day 186 → Part A: Baseline to Follow-Up (Up to 85 Days); Part B: Baseline to Follow-Up (Up to 113 Days); Part C: Baseline to Follow-Up (Up to 183 Days)
    Secondary outcomes 2 edited, 6 added
    What changed in the outcomes
    • EditedPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3844583 - Part A (SAD)Time frame: Pre-dose on Day 1 up to 186 days post-dose → Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
    • EditedPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3844583 - Part A (SAD)Time frame: Pre-dose on Day 1 up to 186 days post-dose → Part A (SAD): Day 1 (Predose, end of infusion (IV route Cohorts 4 and 5 only), 3, 6, 12, 24, 48, 72, 96, 120, 144, 240, 336, 504, 672, 1008, 1344, 1680, 2016 hours postdose)
    • AddedPK: Cmax of LY3844583 - Part B (MAD - Cohort 1)Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
    • AddedPK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ) of LY3844583 - Part B (MAD - Cohort 1)Time frame: Part B (MAD - Cohort 1): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336 hours postdose)
    • AddedPK: Cmax of LY3844583 - Part B (MAD - Cohort 2)Time frame: Part B (MAD - Cohort 2): Day 1 (predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 240, 336, 672, 1344, 1848, 2016 hours postdose)
    • AddedPK: AUCτ of LY3844583 - Part B (MAD - Cohort 2)Time frame: Part B (MAD - Cohort 2): Day 1 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144, 168 hours postdose); Day 29 (Predose, end of infusion, 3, 6, 12, 24, 48, 96, 144 hours postdose)
    • AddedPK: Cmax of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
    • AddedPK: AUCτ of LY3844583 - Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)Time frame: Part C: 1000 mg LY3844583 IV Q2W (Cohort 1) : Day 1 (Predose, end of infusion, 3, 6, 72, 168, 336 hours postdose); Day 85: (Predose, end of infusion, 3, 6 and 72 hours postdose)
    Interventions Added Drug: LY3844583·Drug: Placebo. Arms added: Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3)·Part A: Placebo IV (SAD - Cohort 4-5)·Part A: 30 mg LY3844583 SC (SAD - Cohort 1)·Part A: 100 mg LY3844583 SC (SAD - Cohort 2)·Part A: 300 mg LY3844583 SC (SAD - Cohort 3)·and 7 more
    All 12

    Part A: Placebo SC (Single Ascending Dose [SAD] - Cohort 1-3) · Part A: Placebo IV (SAD - Cohort 4-5) · Part A: 30 mg LY3844583 SC (SAD - Cohort 1) · Part A: 100 mg LY3844583 SC (SAD - Cohort 2) · Part A: 300 mg LY3844583 SC (SAD - Cohort 3) · Part A: 300 mg LY3844583 IV (SAD - Cohort 4) · Part A: 1000 mg LY3844583 IV (SAD - Cohort 5) · Part B: Placebo IV (Multiple Ascending Dose [MAD] - Cohort 1-2) · Part B: 300 mg LY3844583 IV Q2W (MAD - Cohort 1) · Part B: 1000 mg LY3844583 IV QW (MAD - Cohort 2) · Part C: Placebo IV Q2W · Part C: 1000 mg LY3844583 IV Q2W (Cohort 1)

    ; arms removed: LY3844583 (Part A)·LY3844583 (Part B)·LY3844583 (Part C)·Placebo (Part A)·Placebo (Part B)·and 1 more
    All 6

    LY3844583 (Part A) · LY3844583 (Part B) · LY3844583 (Part C) · Placebo (Part A) · Placebo (Part B) · Placebo (Part C)

    + 4 other changes: verification date, description, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05486208
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Aug 11, 2022
Primary completion
Jan 20, 2024
Completion
Jan 20, 2024
Results posted
Oct 13, 2026
Last update
Oct 13, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion